Date:1/26/2012

,684)(2,522)  Amortization of terminated patent license(5,372)-(5,372)-  Amortization of purchased intangible assets(347)(394)(1,383)(1,422)Non-GAAP measure of cost of product sales$
32,470$
25,489$
4,401$
,191Gross margin on product sales per GAAP50%53%54%49%Gross margin on product sales per Non-GAAP58%55%57%51%Operating expenses$
41,293$
29,224$
46,057$
5,871  Stock compensation expense(4,806)(3,614)(18,084)(14,093)  Amortization of purchased intangible assets(107)(78)(429)(409)Non-GAAP measure of operating expenses$
36,380$
25,532$
27,544$
91,369Income (loss) from operations$
(1,393)$
,839$
3,815$
(5,344)  Stock compensation expense5,2494,30119,76816,615  Amortization of terminated patent license5,372-5,372-  Amortization of purchased intangible assets4544721,8121,831Non-GAAP measure of income from operations$
9,682$
,612$
30,767$
3,102Net income (loss)$
(1,649)$
,345$
2,627$
(5,917)  Stock compensation expense5,2494,30119,76816,615  Amortization of terminated patent license5,372-5,372-  Amortization of purchased intangible assets4544721,8121,831Non-GAAP measure of net income$
9,426$
,118$
29,579$
2,529Basic net income (loss) per share$
(0.03)$
.02$
.04$
(0.10)  Stock compensation expense0.080.070.320.28  Amortization of terminated patent license0.09-0.08-  Amortization of purchased intangible assets0.010.010.030.03Non-GAAP measure of net income per share$
.15$
.10$
.47$
.21Diluted net income (loss) per share$
(0.03)$
.02$
.04$
(0.10)  Stock compensation expense0.080.060.290.27  Amortization of terminated patent license0.08-0.08-  Amortization of purchased intangible assets0.010.010.030.03Non-GAAP measure of net income per share$
.14$
.09$
.44$
.20Shares used in computing Non-GAAP basic net income (loss) per share64,11360,41362,73559,712Shares used in com
'/>"/>

SOURCE Cepheid Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Cepheid Welcomes Senior Vice President of Human Resources
2. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
3. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
4. Cepheid to Webcast Upcoming Financial Presentations
5. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
6. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
8. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
9. Cepheid Reports 2009 First Quarter Results
10. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
11. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)